C. De-giovanni, L. Landuzzi, G. Nicoletti, P. L. Lollini, and P. Nanni, Molecular and cellular biology of rhabdomyosarcoma, Future Oncol, vol.5, pp.1449-1475, 2009.

J. F. Shern, Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusionpositive and fusion-negative tumors, Cancer Discov, vol.4, pp.216-231, 2014.

F. G. Barr, Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma, Oncogene, vol.20, pp.5736-5746, 2001.

A. S. Pappo, Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group, J. Clin. Oncol, vol.17, pp.3487-3493, 1999.

A. T. Byrne, Interrogating open issues in cancer precision medicine with patient-derived xenografts, Nat. Rev. Cancer, vol.17, pp.254-268, 2017.

X. Chen, Targeting oxidative stress in embryonal rhabdomyosarcoma, Cancer Cell, vol.24, pp.710-724, 2013.

S. Dietrich, Drug-perturbation-based stratification of blood cancer, J. Clin. Invest, vol.128, pp.427-445, 2018.

C. Pauli, Personalized in vitro and in vivo cancer models to guide precision medicine, Cancer Discov, vol.7, pp.462-477, 2017.

B. Snijder, Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study, Lancet Haematol, vol.4, pp.595-606, 2017.

T. Pemovska, Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia, Cancer Discov, vol.3, pp.1416-1429, 2013.

J. W. Tyner, Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening, Cancer Res, vol.73, pp.285-296, 2013.

E. Stewart, Orthotopic patient-derived xenografts of paediatric solid tumours, Nature, vol.549, pp.96-100, 2017.

R. Mayer, Common themes and cell type specific variations of higher order chromatin arrangements in the mouse, BMC Cell Biol, vol.6, p.44, 2005.

E. Y. Chen, Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma, Proc. Natl Acad. Sci. USA, vol.111, pp.5349-5354, 2014.

T. Vleeshouwer-neumann, Histone deacetylase inhibitors antagonize distinct pathways to suppress tumorigenesis of embryonal rhabdomyosarcoma, PLoS ONE, vol.10, p.144320, 2015.

U. Ben-david, Genetic and transcriptional evolution alters cancer cell line drug response, Nature, vol.560, pp.325-330, 2018.

M. Dumble, Discovery of novel AKT inhibitors with enhanced antitumor effects in combination with the MEK inhibitor, PLoS ONE, vol.9, p.100880, 2014.

D. J. Giard, In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors, J. Natl. Cancer Inst, vol.51, pp.1417-1423, 1973.

J. Lee, Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines, Cancer Cell, vol.9, pp.391-403, 2006.

C. U. Persson, Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum, Sci. Rep, vol.7, p.10274, 2017.

T. A. Ince, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun, vol.6, p.7419, 2015.

M. Baker, Reproducibility: respect your cells, Nature, vol.537, pp.433-435, 2016.

D. T. Loo, J. I. Fuquay, C. L. Rawson, and D. W. Barnes, Extended culture of mouse embryo cells without senescence: inhibition by serum, Science, vol.236, pp.200-202, 1987.

R. Kumar, A. Gont, T. J. Perkins, J. E. Hanson, and I. A. Lorimer, Induction of senescence in primary glioblastoma cells by serum and TGFbeta, Sci. Rep, vol.7, p.21561, 2017.

K. Watanabe, A ROCK inhibitor permits survival of dissociated human embryonic stem cells, Nat. Biotechnol, vol.25, pp.681-686, 2007.

B. Guyot and V. Maguer-satta, Blocking TGF-beta and BMP SMAD-dependent cell differentiation is a master key to expand all kinds of epithelial stem cells, Stem Cell Investig, vol.3, p.88, 2016.

T. Sato, Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium, Gastroenterology, vol.141, pp.1762-1772, 2011.

M. F. Olson, Applications for ROCK kinase inhibition, Curr. Opin. Cell Biol, vol.20, pp.242-248, 2008.

G. Westwood, B. C. Dibling, D. Cuthbert-heavens, and S. A. Burchill, Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway, Oncogene, vol.21, pp.809-824, 2002.

A. J. Williamson, B. C. Dibling, J. R. Boyne, P. Selby, and S. A. Burchill, Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38MAPK and up-regulation of the death receptor p75NTR, J. Biol. Chem, vol.279, pp.47912-47928, 2004.

L. Cao, Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer, Cancer Res, vol.70, pp.6497-6508, 2010.

J. G. Taylor, Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models, J. Clin. Invest, vol.119, pp.3395-3407, 2009.

V. Paulson, High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis, Genes Chromosomes Cancer, vol.50, pp.397-408, 2011.

S. Q. Li, Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534), PLoS ONE, vol.8, p.76551, 2013.

M. N. Hayes, Vangl2/RhoA signaling pathway regulates stem cell selfrenewal Programs and Growth in Rhabdomyosarcoma, Cell Stem Cell, vol.22, pp.414-427, 2018.

M. S. Ignatius, In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma, Cancer Cell, vol.21, pp.680-693, 2012.

D. Walter, CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres, PLoS ONE, vol.6, p.19506, 2011.

P. J. Houghton, The pediatric preclinical testing program: description of models and early testing results. Pediatr, Blood Cancer, vol.49, pp.928-940, 2007.

S. Ghilu, Prospective use of the single-mouse experimental design for the evaluation of PLX038A, Cancer Chemother. Pharmacol, vol.85, pp.251-263, 2020.

D. A. Fruman and C. Rommel, PI3K and cancer: lessons, challenges and opportunities, Nat. Rev. Drug Discov, vol.13, pp.140-156, 2014.

E. F. Petricoin and . Iii, Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival, Cancer Res, vol.67, pp.3431-3440, 2007.

E. Stewart, The childhood solid tumor network: a new resource for the developmental biology and oncology research communities, Dev. Biol, vol.411, pp.287-293, 2016.

M. D'antonio, WEP: a high-performance analysis pipeline for wholeexome data, BMC Bioinformatics, vol.14, p.11, 2013.

W. Sun, Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma, Mod. Pathol, vol.28, pp.1214-1224, 2015.

M. J. Aryee, Minfi: a flexible and comprehensive bioconductor package for the analysis of Infinium DNA methylation microarrays, Bioinformatics, vol.30, pp.1363-1369, 2014.

J. P. Fortin, T. J. Triche, and K. D. Hansen, Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi, Bioinformatics, vol.33, pp.558-560, 2017.

R. Pidsley, Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling, Genome Biol, vol.17, p.208, 2016.